KAROLINSKA

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. Karolinska Dev... elopment has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB. The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced. The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companies Karolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
KAROLINSKA
Industry:
Biotechnology Medical Therapeutics
Founded:
2003-01-01
Status:
Closed
Contact:
+46 72 858 32 09
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics Google Universal Analytics Microsoft Exchange Online Amazon Google Maps Microsoft Azure DNS Mobile Optimized
Stock Details
Investments List
Date | Company | Article | Money raised |
---|---|---|---|
2022-06-03 | PharmNovo | Karolinska investment in Venture Round - PharmNovo | 67 M SEK |
2022-05-12 | Modus Therapeutics | Karolinska investment in Post-IPO Debt - Modus Therapeutics | 11.5 M SEK |
2022-02-03 | AnaCardio | Karolinska investment in Debt Financing - AnaCardio | 33 M SEK |
2021-06-17 | AnaCardio | Karolinska investment in Seed Round - AnaCardio | N/A |
2018-11-30 | Aprea | Karolinska investment in Series C - Aprea | 50 M EUR |
2018-09-05 | Forendo Pharma | Karolinska investment in Venture Round - Forendo Pharma | 4 M EUR |
2017-10-04 | Umecrine Cognition | Karolinska investment in Corporate Round - Umecrine Cognition | 20 M SEK |
2016-09-13 | Promimic | Karolinska investment in Venture Round - Promimic | 3.2 M USD |
2015-11-04 | OssDsign AB | Karolinska investment in Venture Round - OssDsign AB | 9.6 M EUR |
2014-10-22 | Forendo Pharma | Karolinska investment in Series A - Forendo Pharma | 12 M EUR |
More informations about "Karolinska"
Organization - Karolinska University Hospital
Karolinska Institutet - a medical university
1 day ago Karolinska Institutet is one of the world’s foremost medical universities. KI accounts for the single largest share of all academic medical research conducted in Sweden and offers …See details»
Karolinska Institute - Wikipedia
The Karolinska Institute (KI; Swedish: Karolinska Institutet; sometimes known as the (Royal) Caroline Institute in English) is a research-led medical university in Solna within the Stockholm urban area of Sweden and one of the foremost medical research institutes globally. The Nobel Assembly at the Karolinska Institute awards the Nobel Prize in Physiology or Medicine. The assembly cons…See details»
Departments - Karolinska Institutet
Karolinska Institutet has 21 departments and Comparative Medicine, Professional Services, Teaching and learning and University Library. Departments A-Z. Department of Cell and …See details»
Karolinska University Hospital - Wikipedia
The Karolinska University Hospital (Swedish: Karolinska universitetssjukhuset) is a teaching hospital affiliated with Karolinska Institutet in Stockholm, Sweden, with two major sites in the …See details»
Nobel Assembly at the Karolinska Institute - Wikipedia
The Nobel Assembly at the Karolinska Institute is a body at Karolinska Institute that awards the Nobel Prize in Physiology or Medicine.It is headquartered in the Nobel Forum on the grounds …See details»
About Karolinska Institutet
Karolinska Institutet is one of the world’s leading medical universities. Our vision is to advance knowledge about life and strive towards better health for all. Karolinska Institutet accounts for the single largest share of all academic …See details»
Karolinska Institute (KI) - University Ranking
Karolinska Institutet (or institute) is one of the world’s leading medical universities. Our vision is to advance knowledge about life and strive towards better health for all. As a university, KI is …See details»
The Nobel Assembly at Karolinska Institutet
The Nobel Assembly has 50 voting members and is composed of professors in medical subjects at Karolinska Institutet in Stockholm, Sweden. Its working body is the Nobel Committee , elected from among its members for a three-year term.See details»
Karolinska University Hospital
6 days ago Are you a nursing leader looking to enhance your skills and drive change in healthcare? Join us for the upcoming Nursing Management Program at Karolinska University Hospital. Explore leadership, innovation, and …See details»
Karolinska Institute and Karolinska University Hospital | European ...
Aug 20, 2018 ‘The Karolinska University Hospital offers general and highly specialized care within a broad spectrum of cardiology’, explained Professor of Cardiology, John Pernow. The …See details»
Karolinska Institutet - Karolinska hospital
Organization Expand Aria Organization Collapse Aria Organization. Mission, vision and values Karolinska Institutet ... Karolinska and KI have a joint ambition to help people and develop the …See details»
Facts about Karolinska Institutet | Karolinska Institutet
Did you know that Karolinska Institutet (KI) is one of the world's leading medical universities? KI is consistently among the highest ranked universities in the world and has been dedicated to …See details»
Your Heart’s Secret: It Has Its Own Nervous System
22 hours ago Source: Karolinska Institute. New research from Karolinska Institutet and Columbia University shows that the heart has a mini-brain – its own nervous system that controls the …See details»
Karolinska Institutet's strategy and core values
Karolinska Institutet's Strategy 2030 is a long-term plan that was established to guide the university's development until 2030. The strategy will strengthen KI's position as one of the …See details»
New research shows that the heart has a mini-brain—its own …
1 day ago by Karolinska Institutet. Neuroanatomy of the adult zebrafish intracardiac nervous system. ... organization and function of neurons within the heart using a combination of …See details»
Mission, vision and values - Karolinska hospital
Organization Expand Aria Organization Collapse Aria Organization. Mission, vision and values Karolinska Institutet ... Karolinska University Hospital is to lead the way in health and …See details»
Karolinska's Annual Report 2023 sums up another ... - Karolinska …
Feb 2, 2024 Organization Expand Aria Organization Collapse Aria Organization. Mission, vision and values Karolinska Institutet History Expand Aria ... Karolinska's ambitious development …See details»
Events and visits - Karolinska hospital
Questions about how Karolinska coped with challenges such as the pandemic and increased demand for care have been on the agenda, as well as topics such as leadership, organization, …See details»
Clinical studies - Karolinska hospital
Karolinska is one of Europe's leading university hospitals. We will be the best at the difficult things and lead the development of healthcare through new treatments, working methods and …See details»